EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross‐Sectional Study

Shujie Dong, Mengmeng Liu, Yuanyuan Zhang, Jinzi Zhang, Qin Han, Xiaohan Chen, Yibo Wu, Wai-Kit Ming

Journal of Evidence-Based Medicine · 2026

DOI: 10.1111/jebm.70176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Evidence-Based Medicine, 2026. Verfasst von Shujie Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Patient Acceptance of Health Care. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, SIRG-CityU Strategic Interdisciplinary Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Clinical trials are regarded as an essential method for developing new treatments and giving patients access to potentially effective medications that are still being studied. This study aimed to evaluate acceptance of participating in clinical trials of new drugs and to further explore the associated factors.

Methods

A population‐based cross‐sectional study was conducted in China from June 20 to August 31, 2022. We collected demographic data and used visual analog scale scores to assess the public's willingness to accept clinical trials of new drugs (range 0–100). Linear regression analysis was adopted to evaluate the factors related to attitudes toward clinical trials of new drugs.

Results

This survey contained 19,710 valid questionnaires to investigate acceptance of participating in clinical trials of new drugs. Participants showed low willingness to accept clinical trials of new drugs, with a mean score of 44.69 out of 100. The results showed that rural residence ( β = 3.00), western China ( β = 3.15), being married ( β = 2.93), older age (31–59 years [ β = 3.84], ≥60 years [ β = 7.71]), having cancer or rare diseases ( β = 5.15), higher monthly household income (>6000 yuan [ β = 1.76]), medical‐related occupations ( β = 8.01), anxiety status (moderate anxiety [ β = 1.83]), moderate to severe anxiety [ β = 2.66]), perceived stress ( β = 0.51), health literacy ( β = 0.21), self‐efficacy ( β = 0.34), and media use ( β = 0.42) were associated with higher acceptance of participating in clinical trials of new drugs. However, central China ( β = –1.65), female sex ( β = –2.29), chronic diseases ( β = –2.45), and medical insurance ( β = –3.78) were associated with lower acceptance of participating in clinical trials of new drugs. Subgroup analysis demonstrated consistent trends across age and chronic disease subgroups.

Conclusions

This reveales low public willingness to accept clinical trials of new drugs. The willingness is affected by marital status, occupation, area of residence, income, health insurance, physical and mental health status, media use, and health literacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicPatient Acceptance of Health CareHumansCross-Sectional StudiesFemaleChinaMiddle AgedMaleAdultSurveys and QuestionnairesAgedYoung Adult

Stichwörter der Autor:innen

clinical trialcross‐sectional studynew drugpublic willingness

Autor:innen und Institutionen

  • Department of Pharmacy, Peking University Third Hospital, Beijing, China.
  • Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.
  • Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
  • Graduate School, Harbin Medical University, Harbin, China.
  • School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Nursing, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.

Förderung

  • National Natural Science Foundation of China
  • SIRG-CityU Strategic Interdisciplinary Research

Zitieren

APA

Dong, S., Liu, M., Zhang, Y., Zhang, J., Han, Q., Chen, X., Wu, Y., & Ming, W. K. (2026). Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross‐Sectional Study. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.70176

Vancouver

Dong S, Liu M, Zhang Y, Zhang J, Han Q, Chen X, et al. Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross‐Sectional Study. Journal of Evidence-Based Medicine. 2026. doi:10.1111/jebm.70176

BibTeX
@article{Dong2026,
  author = {Dong, Shujie and Liu, Mengmeng and Zhang, Yuanyuan and Zhang, Jinzi and Han, Qin and Chen, Xiaohan and Wu, Yibo and Ming, Wai-Kit},
  title = {Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross‐Sectional Study},
  journal = {Journal of Evidence-Based Medicine},
  year = {2026},
  doi = {10.1111/jebm.70176}
}
Kostenlos starten →